Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort.

Martino EA, Mauro FR, Reda G, Laurenti L, Visentin A, Frustaci A, Vigna E, Pepe S, Catania G, Loseto G, Murru R, Chiarenza A, Sportoletti P, Del Principe MI, Laureana R, Coscia M, Galimberti S, Ferretti E, Zucchetto A, Bomben R, Polesel J, Tedeschi A, Rossi D, Trentin L, Trentin L, Neri A, Morabito F, Gattei V, Gentile M.

Open source

DOI: 10.1002/hon.3249
Published: 2024-01-01
Container: Hematol Oncol
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/hon.3249,
  title = {Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort.},
  author = {Martino EA and  Mauro FR and  Reda G and  Laurenti L and  Visentin A and  Frustaci A and  Vigna E and  Pepe S and  Catania G and  Loseto G and  Murru R and  Chiarenza A and  Sportoletti P and  Del Principe MI and  Laureana R and  Coscia M and  Galimberti S and  Ferretti E and  Zucchetto A and  Bomben R and  Polesel J and  Tedeschi A and  Rossi D and  Trentin L and  Trentin L and  Neri A and  Morabito F and  Gattei V and  Gentile M.},
  year = {2024},
  journal = {Hematol Oncol},
  doi = {10.1002/hon.3249},
  url = {https://doi.org/10.1002/hon.3249}
}

RIS

TY  - JOUR
TI  - Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort.
AU  - Martino EA
AU  -  Mauro FR
AU  -  Reda G
AU  -  Laurenti L
AU  -  Visentin A
AU  -  Frustaci A
AU  -  Vigna E
AU  -  Pepe S
AU  -  Catania G
AU  -  Loseto G
AU  -  Murru R
AU  -  Chiarenza A
AU  -  Sportoletti P
AU  -  Del Principe MI
AU  -  Laureana R
AU  -  Coscia M
AU  -  Galimberti S
AU  -  Ferretti E
AU  -  Zucchetto A
AU  -  Bomben R
AU  -  Polesel J
AU  -  Tedeschi A
AU  -  Rossi D
AU  -  Trentin L
AU  -  Trentin L
AU  -  Neri A
AU  -  Morabito F
AU  -  Gattei V
AU  -  Gentile M.
PY  - 2024
JO  - Hematol Oncol
DO  - 10.1002/hon.3249
UR  - https://doi.org/10.1002/hon.3249
ER  -

APA

EA, M., FR, M., G, R., L, L., A, V., A, F., E, V., S, P., G, C., G, L., R, M., A, C., P, S., MI, D. P., R, L., M, C., S, G., E, F., A, Z., R, B., J, P., A, T., D, R., L, T., L, T., A, N., F, M., V, G., & M., G. (2024). Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort.. Hematol Oncol. https://doi.org/10.1002/hon.3249

Source records

europe-pmc · retrieved 2026-09-27T01:10:23.414Z